A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Clinical trial NCT04055818 · RECRUITING
Trial details
- NCT number
- NCT04055818
- Sponsor
- EpiDestiny, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-24
- Primary completion
- 2026-10-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.